224 related articles for article (PubMed ID: 25967746)
21. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
Shojaei F; Lee JH; Simmons BH; Wong A; Esparza CO; Plumlee PA; Feng J; Stewart AE; Hu-Lowe DD; Christensen JG
Cancer Res; 2010 Dec; 70(24):10090-100. PubMed ID: 20952508
[TBL] [Abstract][Full Text] [Related]
22. Co-expression of hepatocyte growth factor and c-met in epithelial odontogenic tumors.
Poomsawat S; Punyasingh J; Vejchapipat P; Larbcharoensub N
Acta Histochem; 2012 Jul; 114(4):400-5. PubMed ID: 21855117
[TBL] [Abstract][Full Text] [Related]
23. Filamin a mediates HGF/c-MET signaling in tumor cell migration.
Zhou AX; Toylu A; Nallapalli RK; Nilsson G; Atabey N; Heldin CH; Borén J; Bergo MO; Akyürek LM
Int J Cancer; 2011 Feb; 128(4):839-46. PubMed ID: 20473907
[TBL] [Abstract][Full Text] [Related]
24. Targeting HGF/c-MET Axis in Pancreatic Cancer.
Pothula SP; Xu Z; Goldstein D; Pirola RC; Wilson JS; Apte MV
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271944
[TBL] [Abstract][Full Text] [Related]
25. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.
Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS
Carcinogenesis; 2014 Aug; 35(8):1891-900. PubMed ID: 24876152
[TBL] [Abstract][Full Text] [Related]
26. c-Met signaling promotes IL-6-induced myeloma cell proliferation.
Hov H; Tian E; Holien T; Holt RU; Våtsveen TK; Fagerli UM; Waage A; Børset M; Sundan A
Eur J Haematol; 2009 Apr; 82(4):277-87. PubMed ID: 19187270
[TBL] [Abstract][Full Text] [Related]
27. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.
Mineo R; Costantino A; Frasca F; Sciacca L; Russo S; Vigneri R; Belfiore A
Endocrinology; 2004 Sep; 145(9):4355-65. PubMed ID: 15192042
[TBL] [Abstract][Full Text] [Related]
28. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation.
Wong AS; Roskelley CD; Pelech S; Miller D; Leung PC; Auersperg N
Exp Cell Res; 2004 Sep; 299(1):248-56. PubMed ID: 15302591
[TBL] [Abstract][Full Text] [Related]
29. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
30. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.
Abounader R; Lal B; Luddy C; Koe G; Davidson B; Rosen EM; Laterra J
FASEB J; 2002 Jan; 16(1):108-10. PubMed ID: 11729097
[TBL] [Abstract][Full Text] [Related]
31. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
[TBL] [Abstract][Full Text] [Related]
32. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies.
Børset M; Seidel C; Hjorth-Hansen H; Waage A; Sundan A
Leuk Lymphoma; 1999 Jan; 32(3-4):249-56. PubMed ID: 10037022
[TBL] [Abstract][Full Text] [Related]
33. HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers.
Zhang H; Feng Q; Chen WD; Wang YD
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30360560
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure.
Liu Y; Tolbert EM; Lin L; Thursby MA; Sun AM; Nakamura T; Dworkin LD
Kidney Int; 1999 Feb; 55(2):442-53. PubMed ID: 9987069
[TBL] [Abstract][Full Text] [Related]
35. Hepatocyte growth factor and Met in drug discovery.
Sakai K; Aoki S; Matsumoto K
J Biochem; 2015 May; 157(5):271-84. PubMed ID: 25770121
[TBL] [Abstract][Full Text] [Related]
36. Clinical and prognostic value of the C-Met/HGF signaling pathway in cervical cancer.
Boromand N; Hasanzadeh M; ShahidSales S; Farazestanian M; Gharib M; Fiuji H; Behboodi N; Ghobadi N; Hassanian SM; Ferns GA; Avan A
J Cell Physiol; 2018 Jun; 233(6):4490-4496. PubMed ID: 29058790
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
[TBL] [Abstract][Full Text] [Related]
38. [Prognostic significance and molecular targeting therapy of hepatocyte growth factor (HGF) in multiple myeloma].
Hattori Y
Rinsho Ketsueki; 2008 Jun; 49(6):359-66. PubMed ID: 18646602
[No Abstract] [Full Text] [Related]
39. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
40. Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth.
Giannoni P; Fais F; Cutrona G; Totero D
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30642077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
